PRECLINICAL SAFETY AND IMMUNOGENICITY OF CONTREVIR IN CHIMPANZEES

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 这项研究的主要目的是开发一种安全有效的免疫疗法来治疗HIV-1感染。因此，将给两只自然黑猩猩接种一种基因缺失的HIV-1分离株，命名为Contrevir，它不会引起疾病，但具有复制能力。将两只HIV病毒感染的黑猩猩静脉接种缺陷病毒，在不同的时间点采集血液和淋巴结活检样本，以确定病毒的复制和宿主对病毒的免疫应答。此外，还将监测血细胞计数和临床化学参数，以确定安全性。预计给药将是安全的，并将在黑猩猩身上诱导强大的免疫反应。如果Contrevir是安全有效的，它将为艾滋病毒/艾滋病的治疗增加一种免疫疗法

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The primary objective of this study is to develop a safe and effective immunotherapy for HIV-1 infection.Therefore, two na¿ve chimpanzees will be inoculated with a gene deleted HIV-1 isolate designated as Contrevir which is non-disease causing but replication competent. Two HIV na¿ve chimpanzees will be intravenously inoculated with the defective virus , blood and lymph node biopsy samples will be collected at various time points to determine replication of the virus and immunological response of the host to the virus. In addition blood cell counts and clinical chemistry parameters will be monitored to determine safety aspects. It is anticipated that administration of Contrevir will be safe and will induce robust immune responses in chimpanzees. If Contrevir is safe and effective, it will add an immunotherapy approach to the treatment of HIV/AIDS